Singulair
Sponsors
GlaxoSmithKline, Yuhan Corporation, Roxane Laboratories, Genuine Research Center, Egypt, Pharmtechnology LLC
Conditions
AsthmaHealthyHealthy Adults
Early Phase 1
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions
CompletedNCT01659892
Start: 2008-08-31End: 2008-08-31Updated: 2018-01-23
Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions
CompletedNCT01659918
Start: 2008-02-29End: 2008-02-29Updated: 2018-01-23
Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions
CompletedNCT01659931
Start: 2008-02-29End: 2008-02-29Updated: 2018-01-23
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions
CompletedNCT01659905
Start: 2008-08-31End: 2008-08-31Updated: 2018-01-23
Phase 1
Study With GW274150 In Patients With Mild Asthma
CompletedNCT00273013
Start: 2004-11-15End: 2005-10-28Updated: 2017-10-18
A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)
CompletedNCT02480049
Start: 2014-08-31End: 2014-08-31Updated: 2015-06-24
Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)
CompletedNCT02479854
Start: 2014-04-30End: 2014-04-30Updated: 2015-06-24
Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions
CompletedNCT03898193
Start: 2019-03-23End: 2019-04-08Updated: 2019-06-06